The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 227.50
Bid: 226.50
Ask: 228.00
Change: 2.00 (0.89%)
Spread: 1.50 (0.662%)
Open: 228.00
High: 228.50
Low: 224.50
Prev. Close: 225.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Puretech Health proposes $100m capital return

Tue, 19th Mar 2024 09:46

(Sharecast News) - Biotherapeutics company PureTech Health has proposed a capital return of $100.0m to its shareholders by way of a tender offer.

PureTech said on Tuesday that the proposed capital return represented approximately 14% of its market capitalisation based on Monday's closing price and noted that it follows a previous announcement that it will receive approximately $293.0m in gross proceeds from its remaining stake in Karuna.

The AIM-listed group said the offer will be launched after the publication of its full-year results in April, subject to market conditions, and will require shareholder approval.

PureTech added that if the full $100.0m was not returned, then it intends to return any remainder following the completion of the offer, by way of a special dividend.

Chief executive Daphne Zohar said: "PureTech's mission is to generate value both for patients and shareholders, and Bristol Myers Squibb's acquisition of our Founded Entity Karuna Therapeutics for $14.0bn is a testament to our execution on both fronts. We directed $18.5m to the founding and development of Karuna, and not only have we created a potential breakthrough treatment that may change the lives of millions of people living with schizophrenia, but we have also been able to generate $1.1bn in cash for PureTech, with potentially more to come. These resources enabled us to create an exciting crop of new medicines that position us to repeat and scale this type of outcome - and we have done so without diluting our shareholders in over six years.

"We are delighted to be able to purchase shares of PureTech at this valuation and to concurrently provide some liquidity to our shareholders and additional capital returns beyond the recently completed $50.0m share buyback. Following this proposed tender offer, we are confident that our strong balance sheet will continue to support the development of our existing pipeline - as well as the next wave of innovative medicines. Looking forward, the board will continue to assess ongoing opportunities to improve shareholder returns."

As of 1055 GMT, PureTech shares were up 8.58% at 221.50p.

Reporting by Iain Gilbert at Sharecast.com

More News
7 Jul 2020 16:35

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

Read more
23 Jun 2020 07:29

PureTech's Akili gets CE-mark for 'EndeavourRx'

(Sharecast News) - Biotherapeutics company PureTech Health said its founded entity Akili had received a CE-mark for 'EndeavorRx treatment for attention deficit hyperactivity disorder (ADHD).

Read more
18 Jun 2020 18:49

IN BRIEF: Puretech Health Partners With China Medical System

IN BRIEF: Puretech Health Partners With China Medical System

Read more
16 Jun 2020 14:34

IN BRIEF: PureTech's Akili In Green Light For Video Game ADHD Therapy

IN BRIEF: PureTech's Akili In Green Light For Video Game ADHD Therapy

Read more
16 Jun 2020 07:29

PureTech gets FDA clearance for video game ADHD treatment

(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health announced on Tuesday that its subsidiary Akili has been granted US Food and Drug Administration (FDA) clearance for 'EndeavorRx', or AKL-T01, as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD).

Read more
9 Jun 2020 13:25

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Read more
9 Jun 2020 08:40

PureTech Health sees 'positive' topline data from Phase 1 on IBD candidate

(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health reported some "positive" topline data from two Phase 1 studies into VE202, its orally-administered inflammatory bowel disease treatment candidate.

Read more
4 Jun 2020 13:19

UK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service

UK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service

Read more
2 Jun 2020 12:57

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

Read more
2 Jun 2020 07:37

PureTech firm Gelesis gets Europe approval for 'Plenity'

(Sharecast News) - Clinical stage biotherapeutics company PureTech Health announced on Tuesday that its founded company Gelesis has received approval to market 'Plenity', a novel weight-loss treatment, in Europe.

Read more
28 May 2020 14:49

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

Read more
28 May 2020 07:57

PureTech to advance LYT-100 as potential Covid treatment

(Sharecast News) - PureTech Health announced plans on Thursday to advance its wholly-owned clinical-stage product candidate 'LYT-100', or deupirfenidone, as a potential treatment for serious respiratory complications, including inflammation and fibrosis, that persist following the resolution of Covid-19 infection.

Read more
26 May 2020 14:22

UK EXECUTIVE CHANGE SUMMARY: New Chairs For Matomy And Shield

UK EXECUTIVE CHANGE SUMMARY: New Chairs For Matomy And Shield

Read more
26 May 2020 08:51

PureTech Health lowers stake in founded entity

(Sharecast News) - Clinical stage biotechnology company PureTech Health said on Tuesday that it had received $45m from the sale of 555,500 shares of its founded entity Karuna Therapeutics.

Read more
18 May 2020 13:46

UK DIRECTOR DEALINGS SUMMARY: Novacyt Chair And CEO Step In To Buy

UK DIRECTOR DEALINGS SUMMARY: Novacyt Chair And CEO Step In To Buy

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.